Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

NCT06725693 · Recruiting

Last updated 2026-05-28

This clinical trial is testing a new imaging method using a radioactive tracer to detect GLP-1 receptor-related diseases, such as tumors or insulinomas, in patients using a PET/CT scan.

Status Recruiting Currently enrolling participants.

Type Observational

Participants 500 people Planned (estimated).

Who can join Ages 18–80 · all sexes Healthy volunteers accepted.

Timeline Started 2019-02 · est. completion 2027-11

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06725693 ↗

Description as written by the study sponsor.

To evaluate the potential usefulness of 68Ga/18F-Exendin 4 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.

Treatments tested

18F/68Ga-Exendin 4 Diagnostic test

Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.

Main thing measured	Standardized uptake value (SUV)
Sponsor	Tianjin Medical University
Conditions studied	GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06725693 ↗